Sujatha Gurunathan

Blog Post

FDA Approves Sarepta’s ELEVIDYS for Treatment of DMD

By Sujatha Gurunathan | June 22, 2023
Blog Post

FDA Approves argenx’s Vyvgart Hytrulo for Treatment of gMG

By Sujatha Gurunathan | June 20, 2023
Blog Post

Research Study Alert: Natural History Study in Males with BMD

By Sujatha Gurunathan | June 8, 2023
Clinical Trial Alert with image of researcher's gloved hand holding a test tube
Blog Post

Clinical Trial: Phase 1/2 Study of BIIB105 in Individuals with ALS

By Sujatha Gurunathan | May 8, 2023
Research Study Alert with image of researcher writing on clipboard
Blog Post

Research Study Alert: Survey for Working Caregivers of Children with DMD

By Sujatha Gurunathan | May 8, 2023
A female doctor or nurse concentrates while reviewing at a patient's test results.
Blog Post

The Value of Natural History Studies for Neuromuscular Disease

By Sujatha Gurunathan | May 4, 2023
Motor neuron connecting to muscle fiber, 3D illustration. A neuromuscular junction allows the motor neuron to transmit a signal to the muscle causing contraction. It is affected by toxins and diseases
Blog Post

Simply Stated: Research Updates in Emery-Dreifuss Muscular Dystrophy (EDMD)

By Sujatha Gurunathan | April 28, 2023
Green background with word Clinical Trial Alert and a picture of scientists in a lab
Blog Post

Clinical Trial Alert: Phase 3 Study of Pozelimab and Cemdisiran in Adults with gMG

By Sujatha Gurunathan | April 26, 2023
FDA approved Biogen’s Qalsody for treatment of SOD1-ALS.
Blog Post

FDA Approves Biogen’s Qalsody for Treatment of SOD1-ALS

By Sujatha Gurunathan | April 25, 2023
Digital background depicting innovative technologies in genetic research
Blog Post

Simply Stated: Research Updates in Pompe Disease

By Sujatha Gurunathan | March 29, 2023